Connect with us

The Americas

Major European fund targets health tech innovators

Avatar photo



One of Europe’s most substantial health tech innovation funds has emerged following the closing of Lauxera’s debut fund at more than €260m (£218m). 

Lauxera Growth I  exceeded its initial fundraising target of €150 million, reflecting the strength and depth of the investment opportunities in fast-growing European health tech sector.

Lauxera Growth I makes investments in health tech innovators, aiming to help founders and managers drive international commercialisation, particularly in the US market.

It invests up to €20-40 million in each company and more with the support of its limited partners.

Pierre Moustial, chairman and co-founder of Lauxera Capital Partners said: “[The fund’s] size and the quality of its limited partners allow us to operate at the same level as the largest American specialist funds financing health tech innovators with global ambitions.

“We can accelerate the international growth of our portfolio companies and transform them into multi- national champions in HealthTech. Over the past year, we have invested close to 25 per cent of the fund’s final size in five companies, playing active governance and advisory roles to accelerate their growth.”

Among its first five investments, Lauxera Growth I acted as lead or co-lead investor in the latest financing rounds of Reapplix (Denmark), LUMICKS (Netherlands), Caresyntax (Germany & USA), and Lifen (France), and led the acquisition of a majority stake in Groupe PSIH (France).

Dr. Samuel Levy and Alex Slack, co-founders of Lauxera Capital Partners, said in a joint statement: “From the outset, our vision has been to position our fund as a key player in supporting the scale-up of European health tech companies.

“As the critical challenge for these companies is to quickly penetrate the US market, our network, our regulatory and commercial skills, and our transatlantic positioning naturally make us the ideal partner.

“Europe has an unparalleled wealth of healthcare innovations and an array of great medical technology companies in healthcare software, medical devices, research tools, digital health, and biomanufacturing that can radically improve the efficiency of our healthcare systems while improving outcomes for patients.”

Lauxera Growth I has been awarded the label “Plan de Financement de la Tech” (“Plan Tibi”) by the French Government as part of its charter with participating institutional investors aimed at enhancing financing opportunities for technology companies.

Founded in January 2020, Lauxera Capital Partners is an independent, health tech-focused investment firm based in Paris and San Francisco.

The closing of its first fund was supported by investors such as Covea, Candriam and Bpifrance, the French national investment bank, which invested in equity and through its Growth fund of fund on behalf of private insurers and the French public financial institution Caisse des Dépôts.

Major European family offices also participated such as Tethys, Compagnie Nationale à Portefeuille (CNP), Financière Dassault, and Italmobiliare

Continue Reading
1 Comment

1 Comment

  1. Pingback: Nina's new fund has health tech in its sights - Health Tech World

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories